Navigation Links
NeoVista Presents Interim Study Results of Novel Therapy for the Treatment of Neovascular Age-Related Macular Degeneration
Date:10/27/2009

Data suggests that Epimacular Brachytherapy may reduce the burden of treatment and further improve Visual Acuity

San Francisco, CA (PRWEB) October 27, 2009 -- NeoVista, Inc. made public at the American Academy of Ophthalmology meeting the company's interim study results from the preliminary study MERITAGE-I. The study was designed to examine the company's novel epimacular brachytherapy procedure when used in patients that require chronic therapy with anti-VEGF agents on an ongoing basis to control their neovascular AMD. The study enrolled patients that had as many as 23 injections of anti-VEGF therapy before receiving epimacular brachytherapy. All patients that entered the study were required to have received a minimum of 8 injections in the past 12 months or 6 injections in the past 6 months preceding enrollment. Preliminary study results (n=16) suggest that a single procedure of epimacular brachytherapy can further improve visual acuity in a majority of this patient population while decreasing the number of injections required based on Optical Coherence Tomography imaging after the brachytherapy procedure. Most importantly, 63% of patients enrolled in the study experienced improvement in their visual acuity while 50% of patients gained 5 or more letters of visual acuity at 6 months.

"MERITAGE-I is the first of its kind study designed to evaluate the potential role of our device in decreasing the current burden of treatment while maintaining or improving visual acuity," said John N. Hendrick, President and CEO of NeoVista. "Data from recent randomized trials suggest that most patients suffering from neovascular AMD will require treatment on an ongoing basis for an indefinite period of time. We are very excited that our device has the potential to significantly decrease the number of injections administered in this patient population and may also improve visual acuity in a
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. FDA Grants NeoVistas Request to Utilize Novel Wet AMD Treatment in Compassionate Case
2. NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting
3. Morehead Presents Webinar on 'A Two-Pronged Strategy to Reduce Nurse Turnover'
4. Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
5. YWCA Greater Los Angeles Presents Black & White Benefactrix Ball
6. Hospice Foundation of America Presents Webinar on Grief, Holidays, and Family Dynamics
7. CEL-SCI Presents Data at American College of Rheumatology Conference Which Suggests that CEL-2000 Has Potential to Slow Damage Caused by Rheumatoid Arthritis
8. Formatta Presents Forms-Driven Business Process Optimization Webinar for Healthcare on Wednesday, October 14 at 1 p.m. Eastern
9. Morehead Presents Webinar on "Measuring the Organization's Patient Safety Culture"
10. Simmons Law Firm Presents Second Miles for Meso Walk/Run Fundraiser for Mesothelioma Research
11. Simmons Law Firm Presents Second Miles for Meso Walk/Run Fundraiser
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss review that ... loss program ever developed. It promises to provide users the ... no wonder after all that this has become the most ... and workout fat loss program was created by Joel Marion, ... the author of this fat loss system, the method can ...
(Date:10/31/2014)... Lake City, UT (PRWEB) October 31, 2014 ... announce the new Activz Silver line offering ... and cleansing wipes. For over a century, silver has ... formula found in Activz Silver products is the most ... U.S. patents, has a unique chemical structure that supports ...
(Date:10/31/2014)... In terms of duration of treatment and cost, ... from accelerated partial breast irradiation (APBI) with proton ... new research from The University of Texas MD ... a cost analysis study based on typical patient ... allowable charges for eight different types of partial ...
(Date:10/31/2014)... Colorado (PRWEB) October 31, 2014 The ... that this workout program was developed by Dan Long, ... become well-known as a fitness professional and life coach. ... fat and having toned muscles is not impossible , ... based on suspension training. Suspension training promises efficiency when ...
(Date:10/31/2014)... NY (PRWEB) October 31, 2014 ... the most remarkable gifts of life — building a ... matching extraordinary surrogate mothers and donors with hopeful intended ... in unforeseen circumstances. , It’s a collective aptitude of ... agencies, surrogacy lawyers, and fertility clinics that help provide ...
Breaking Medicine News(10 mins):Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3
... the prosthesis that has helped thousands of disabled worldwide to ... first centre on foreign soil . ,The Colombian government ... of the artificial limb, to set up base in the ... with a Colombia-based NGO. ,M.K. Mathur of BMVSS ...
... disease (STD) has surpassed Neisseria gonorrhea in prevalence among young ... a big menace, researchers say . ,The new ... the 1980s. It can cause inflammation of the urethra (the ... the cervix and the lining of the uterus in women, ...
... on less than 50 pence (Rs.40) a day will benefit from ... the number of children who die before their fifth birthday. ... when mothers give birth, a doctor or nurse is available to ... much better chance of survival. ,Groups at a high ...
... are weak at mathematics, reading, and writing better watch out ... research suggests that such symptoms may cause students to ... Bachmann of Chappaqua Public Schools in New York, the study ... graders, who completed Sleep Disorders Inventory for Students - Child ...
... new genetic cause for Joubert syndrome (JS), an inherited ... brainstem-the structures in the brain that coordinate movements and ... and consciousness. ,This is the fifth gene ... syndrome. Researchers at Seattle Children's Hospital Research Institute, the ...
... University of Washington and other members of an international ... genome functions . While previous studies of the human ... insight into the non-gene sequences making up the vast ... non-gene sequences are so-called "regulatory elements" that contain instructions ...
Cached Medicine News:Health News:Jaipur Foot All Set to Launch Its Centre in Columbia 2Health News:British Funds 250 Million Pounds to Reduce Child Mortality 2Health News:Students With Sleep Disorder Symptoms Score Badly in Maths 2Health News:Boffins Identify Fifth Gene Behind Joubert Syndrome 2Health News:Researchers Cracking the Human Genome Function 2Health News:Researchers Cracking the Human Genome Function 3
(Date:10/31/2014)... Investor-Edge has initiated coverage on the ... Laboratories (NYSE: ABT ), Hologic Inc. (NASDAQ: ... and Covidien PLC (NYSE: COV). Free research on these five ... The US markets on Thursday, October 30, 2014, ended on ... at 17,195.42, up 1.30% and the NASDAQ Composite closed at ...
(Date:10/31/2014)...  Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is ... in combination with gemcitabine, will be reimbursed via the ... cancer from 1 November. In ... th most common cause of cancer mortality. Pancreatic ... the lowest 5-year survival of all common cancers at ...
(Date:10/31/2014)... 31, 2014 Today, Analysts Review ... CELG ), Bristol-Myers Squibb Co. (NYSE: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,Celgene Corporation Research Reports ,On October 23, 2014, Celgene ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
... Jan. 27, 2011 Significant flooding occurred in many ... January 2011.  Thousands of residents were affected.  A disaster ... on 29 December 2010, by Premier of Queensland, Anna ... in to help their fellow citizens clean-up in the ...
... China and ROCKVILLE, Md., Jan. 26, 2011 /PRNewswire-Asia/ -- Synutra ... formula company in China and a producer, marketer and seller ... that it plans to release its financial results for the ... 2011 after market close. The Company will ...
Cached Medicine Technology:DSM Joins International Response to Flooding in Australia 2DSM Joins International Response to Flooding in Australia 3Synutra to Announce Third Quarter Fiscal 2011 Financial Results 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 12 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 11 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 9 mm....
Medicine Products: